Seeking Alpha

Bio-Reference Labs (BRLI +6.5%) pops after BofA Merrill Lynch ups the shares to Buy, citing how...

Bio-Reference Labs (BRLI +6.5%) pops after BofA Merrill Lynch ups the shares to Buy, citing how the returns on the commercialization of its high-end tests in a number of high-growth specialty niches are starting to bear fruit. Additionally, reimbursement headwinds and new billing codes are more likely to disproportionately impact small players, which gives BRLI the opportunity to capture market share.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|